Literature DB >> 10768338

Retinal choroidal anastomoses and occult choroidal neovascularization in age-related macular degeneration.

J S Slakter1, L A Yannuzzi, U Schneider, J A Sorenson, A Ciardella, D R Guyer, R F Spaide, K B Freund, D A Orlock.   

Abstract

OBJECTIVE: This study was designed to identify the incidence of retinal choroidal anastomoses in patients with occult choroidal neovascularization (CNV) and focal hot spots on indocyanine green (ICG) angiography, to identify the clinical and angiographic features that would assist in their identification, and to determine if the presence of these anastomotic lesions affect the outcome of laser therapy.
DESIGN: Combined prospective and retrospective cross-sectional study. PARTICIPANTS: One hundred fifty consecutive patients with newly diagnosed occult CNV secondary to exudative age-related macular degeneration and focal hot spots on ICG angiography were evaluated prospectively. In addition, a retrospective review was performed on 79 eyes previously reported to have undergone laser photocoagulation treatment with ICG guidance. METHODS AND TESTING: In all cases, stereo color and red-free photographs, and stereo fluorescein and digital ICG angiograms were obtained for evaluation. MAIN OUTCOME MEASURES: Images obtained by all four techniques were evaluated for the presence of a retinal choroidal anastomosis. Associated clinical and angiographic findings were noted. In the retrospective review, the success rate of laser treatment was correlated with the presence or absence of a retinal choroidal anastomosis.
RESULTS: Of the 150 eyes evaluated prospectively, 31 (21%) were found to have a retinal choroidal anastomosis. Retinal choroidal anastomoses were found in 27% of patients with associated serous pigment epithelial detachment (PED), whereas 13% were found in those without an associated elevation of the retinal pigment epithelium. Seventy-one percent of eyes had multiple anastomotic connections. Ninety percent of eyes had at least one retinal vein involved in the anastomotic connection. Clinical evidence of preretinal and intraretinal hemorrhage and cystic edema coupled with angiographic evidence of intraretinal dye leakage were key features of retinal choroidal anastomoses. In the retrospective review, seven patients were found to have retinal choroidal anastomoses with associated serous PED and demonstrated a very low (14%) success rate for laser treatment.
CONCLUSIONS: Retinal choroidal anastomoses can present as a primary manifestation of the exudative process in age-related macular degeneration. They may be seen in eyes with and without detachment of the retinal pigment epithelium. Specific clinical and angiographic features have been identified that can aid in the diagnosis of these vascular anomalies. Their presence represents a poor prognostic sign for successful ICG-guided laser treatment.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10768338     DOI: 10.1016/s0161-6420(00)00009-9

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  41 in total

1.  Outcomes in Eyes with Retinal Angiomatous Proliferation in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).

Authors:  Ebenezer Daniel; James Shaffer; Gui-shuang Ying; Juan E Grunwald; Daniel F Martin; Glenn J Jaffe; Maureen G Maguire
Journal:  Ophthalmology       Date:  2015-12-08       Impact factor: 12.079

2.  Retinal angiomatous proliferation: combined therapy of intravitreal triamcinolone acetonide and PDT versus PDT alone.

Authors:  Ilse Krebs; Katharina Krepler; Ulrike Stolba; Alexandra Goll; Susanne Binder
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-08-03       Impact factor: 3.117

3.  Prognosis of untreated occult choroidal neovascularization.

Authors:  Ilse Krebs; Ulrike Stolba; Carl Glittenberg; Orang Seyeddain; Thomas Benesch; Susanne Binder
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-10-27       Impact factor: 3.117

4.  Types of choroidal neovascularisation in newly diagnosed exudative age-related macular degeneration.

Authors:  S Y Cohen; C Creuzot-Garcher; J Darmon; T Desmettre; J F Korobelnik; F Levrat; G Quentel; S Paliès; A Sanchez; A Solesse de Gendre; H Schluep; M Weber; C Delcourt
Journal:  Br J Ophthalmol       Date:  2007-03-23       Impact factor: 4.638

5.  Surgical excision of neovascularization in retinal angiomatous proliferation.

Authors:  Hiroyuki Shimada; Ryuzaburo Mori; Keiko Arai; Akiyuki Kawamura; Mitsuko Yuzawa
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-12-17       Impact factor: 3.117

6.  High resolution Fourier-domain optical coherence tomography of retinal angiomatous proliferation.

Authors:  Steven N Truong; Suhail Alam; Robert J Zawadzki; Stacey S Choi; David G Telander; Susanna S Park; John S Werner; Lawrence S Morse
Journal:  Retina       Date:  2007-09       Impact factor: 4.256

7.  Photodynamic therapy with verteporfin for retinal angiomatous proliferation.

Authors:  Francesco Boscia; Maurizio Battaglia Parodi; Claudio Furino; Michele Reibaldi; Carlo Sborgia
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-03-09       Impact factor: 3.117

8.  The prevalence of retinal angiomatous proliferation in age-related macular degeneration with occult choroidal neovascularization.

Authors:  Amedeo L Massacesi; Laura Sacchi; Fulvio Bergamini; Ferdinando Bottoni
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-07-25       Impact factor: 3.117

9.  Three dimensional spectral domain optical coherence tomography features of retinal-choroidal anastomosis.

Authors:  Giuseppe Querques; Fernando O Avellis; Lea Querques; Nathalie Massamba; Francesco Bandello; Eric H Souied
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-08-23       Impact factor: 3.117

10.  Two-year results of combined intravitreal ranibizumab and photodynamic therapy for retinal angiomatous proliferation.

Authors:  Masaaki Saito; Tomohiro Iida; Mariko Kano; Kanako Itagaki
Journal:  Jpn J Ophthalmol       Date:  2016-01       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.